Mather Group LLC. Sells 70 Shares of HCA Healthcare, Inc. (NYSE:HCA)

Mather Group LLC. trimmed its position in shares of HCA Healthcare, Inc. (NYSE:HCA) by 5.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,138 shares of the company’s stock after selling 70 shares during the period. Mather Group LLC.’s holdings in HCA Healthcare were worth $342,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of HCA. Marshall Wace LLP purchased a new position in shares of HCA Healthcare during the second quarter valued at about $514,000. Czech National Bank grew its holdings in shares of HCA Healthcare by 2.5% during the 3rd quarter. Czech National Bank now owns 37,852 shares of the company’s stock worth $15,384,000 after acquiring an additional 918 shares during the period. Atomi Financial Group Inc. bought a new stake in shares of HCA Healthcare during the third quarter valued at approximately $233,000. Artemis Investment Management LLP purchased a new position in HCA Healthcare during the third quarter valued at $13,280,000. Finally, Brookstone Capital Management grew its position in shares of HCA Healthcare by 0.7% in the 3rd quarter. Brookstone Capital Management now owns 4,065 shares of the company’s stock worth $1,652,000 after buying an additional 30 shares during the period. Institutional investors own 62.73% of the company’s stock.

HCA Healthcare Stock Performance

Shares of NYSE HCA opened at $324.33 on Friday. HCA Healthcare, Inc. has a 12-month low of $289.98 and a 12-month high of $417.14. The firm has a 50 day moving average of $313.88 and a 200 day moving average of $353.57. The company has a current ratio of 1.08, a quick ratio of 0.97 and a debt-to-equity ratio of 69.07. The firm has a market capitalization of $82.15 billion, a price-to-earnings ratio of 14.76, a price-to-earnings-growth ratio of 1.13 and a beta of 1.64.

HCA Healthcare (NYSE:HCA) last issued its quarterly earnings results on Friday, January 24th. The company reported $6.22 EPS for the quarter, topping analysts’ consensus estimates of $6.03 by $0.19. HCA Healthcare had a return on equity of 586.47% and a net margin of 8.16%. During the same period in the previous year, the business earned $5.90 earnings per share. On average, research analysts anticipate that HCA Healthcare, Inc. will post 24.89 earnings per share for the current year.

HCA Healthcare Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 17th will be paid a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a yield of 0.89%. The ex-dividend date of this dividend is Monday, March 17th. This is a positive change from HCA Healthcare’s previous quarterly dividend of $0.66. HCA Healthcare’s dividend payout ratio is presently 13.11%.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on HCA. Barclays decreased their target price on shares of HCA Healthcare from $392.00 to $366.00 and set an “overweight” rating for the company in a research note on Monday, January 27th. Morgan Stanley dropped their target price on HCA Healthcare from $406.00 to $355.00 and set an “equal weight” rating on the stock in a report on Tuesday, December 17th. StockNews.com cut shares of HCA Healthcare from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. Bank of America dropped their target price on shares of HCA Healthcare from $380.00 to $370.00 and set a “buy” rating on the stock in a research note on Monday, January 27th. Finally, JPMorgan Chase & Co. restated a “neutral” rating and issued a $380.00 price objective on shares of HCA Healthcare in a report on Tuesday, December 17th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $385.67.

Insider Transactions at HCA Healthcare

In other HCA Healthcare news, SVP Phillip G. Billington sold 3,897 shares of the business’s stock in a transaction on Thursday, November 14th. The shares were sold at an average price of $350.00, for a total value of $1,363,950.00. Following the sale, the senior vice president now owns 52,702 shares in the company, valued at $18,445,700. The trade was a 6.89 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Erol R. Akdamar sold 2,900 shares of the business’s stock in a transaction dated Thursday, November 14th. The stock was sold at an average price of $353.00, for a total value of $1,023,700.00. Following the completion of the sale, the insider now owns 6,843 shares in the company, valued at $2,415,579. This represents a 29.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company’s stock.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.